Ortivus AB
Ortivus AB is a provider of advanced medical equipment and technology, primarily generating revenue through the development, production, and sale of medical devices and related services.
Business. Ortivus AB (ORTIB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Ortivus AB (ORTIB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Ortivus AB has a liquidity position that is marginally balanced, with a current ratio of 0.98, indicating that its current liabilities slightly exceed its current assets. The company's liquidity is further constrained by a negative net cash position after subtracting total debt, which is a key flag in its risk assessment. The company's cash and equivalents amount to 8,888,000 SEK, while its long-term debt stands at 19,527,000 SEK, resulting in a debt-to-equity ratio of 0.87.
Profitability metrics for Ortivus are weak, with a return on equity (ROE) of -0.976 and a return on assets (ROA) of -0.3084, both significantly below the industry median for Advanced Medical Equipment & Technology firms. The company reported a net loss of 21,876,000 SEK and an operating loss of 19,805,000 SEK, reflecting poor operational performance. Gross profit of 29,600,000 SEK is insufficient to cover operating expenses, contributing to the negative net income.
Geographically and segment-wise, Ortivus does not disclose detailed revenue concentration data in the provided financials. However, the company operates in a specialized segment of the healthcare industry, and its business model is likely concentrated in a few core product lines or geographic regions, as is typical for firms in the Advanced Medical Equipment & Technology industry.
The company's growth trajectory is uncertain, with no specific outlook provided for the current or next fiscal year. Historical revenue of 73,401,000 SEK suggests a relatively small revenue base, and the negative operating and free cash flows indicate that the company is not generating sufficient cash to sustain operations without external financing. The capital expenditure of -9,593,000 SEK suggests ongoing investment in infrastructure or equipment, but this is being funded by negative cash flows rather than positive operating performance.
Risk factors for Ortivus include its liquidity constraints and the potential for dilution, although the risk of dilution is currently assessed as low. The company's negative net cash position and operating cash flow of -25,238,000 SEK raise concerns about its ability to meet short-term obligations without additional financing. The risk assessment also highlights the need for close monitoring of the company's capital structure and cash flow generation.
Recent events, including the latest financial filing (market data), indicate that the company is in a challenging financial position. The operating and net losses, combined with negative cash flows, suggest that the company may need to secure additional financing or restructure its operations to improve its financial health.
- Ortivus AB is a small-cap healthcare equipment firm with a weak profitability profile and negative cash flows.
- The company's liquidity is constrained, with a current ratio of 0.98 and a negative net cash position after debt.
- Return on equity and return on assets are significantly below industry medians, indicating poor capital efficiency.
- The company is not generating sufficient cash to fund operations or capital expenditures.
- The risk of dilution is currently low, but liquidity risk remains a concern.
- No clear growth trajectory is evident from the provided data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Ortivus AB Market data — financials · 2026-05-28